Literature DB >> 29580436

The Surgical Management of Prostate Cancer.

Elisabeth M Sebesta1, Christopher B Anderson2.   

Abstract

Prostate cancer is a heterogeneous disease with a variable natural history. Therefore, optimal management remains challenging. While many men with newly diagnosed prostate cancer may be candidates for active surveillance, there are others who will benefit from aggressive local therapy. Radical prostatectomy is associated with improvements in cancer-specific mortality, metastasis-free survival, and need for palliative treatments when compared with observation in several randomized controlled trials. Additionally, radical prostatectomy may have some oncologic benefit over radiation therapy. All aggressive therapy for prostate cancer negatively impacts erectile function and urinary continence. The decision for which treatment modality to pursue should incorporate shared decision making and consider cancer risk and severity in addition to patient preferences.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  prostatectomy; prostatic neoplasms; urologic neoplasm

Mesh:

Substances:

Year:  2018        PMID: 29580436     DOI: 10.1053/j.seminoncol.2018.01.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  17 in total

1.  microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ERβ.

Authors:  Zhenming Jiang; Yuxi Zhang; Xi Chen; Yan Wang; Pingeng Wu; Chengzhang Wu; Dong Chen
Journal:  J Transl Med       Date:  2020-05-24       Impact factor: 5.531

2.  Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml-1).

Authors:  Jun Liu; Zhi-Qian Wang; Min Li; Ming-Yang Zhou; Yi-Fei Yu; Wei-Wei Zhan
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

Review 3.  Circular RNAs: Promising Biomarkers for Age-related Diseases.

Authors:  Yan-Hong Pan; Wei-Peng Wu; Xing-Dong Xiong
Journal:  Aging Dis       Date:  2020-12-01       Impact factor: 6.745

4.  LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.

Authors:  Hailong Hao; Huiqing Chen; Liwu Xie; Hongyu Liu; Dongwen Wang
Journal:  Onco Targets Ther       Date:  2021-03-03       Impact factor: 4.147

5.  Acupuncture for prostatectomy incontinence: study protocol for a multicenter single-blind randomized parallel controlled trial.

Authors:  Yao Zhang; Shanqi Guo; Chaoran Wang; Xiaodi Liu; Yan Liu; Hongcai Shang; Peiying Yang; Liang Wang; Jingbo Zhai; Xiaojiang Li; Yingjie Jia
Journal:  Trials       Date:  2022-01-04       Impact factor: 2.279

6.  UBC Mediated by SEPT6 Inhibited the Progression of Prostate Cancer.

Authors:  Ruochen Zhang; Yaojing Yang; Haijian Huang; Tao Li; Liefu Ye; Le Lin; Yongbao Wei
Journal:  Mediators Inflamm       Date:  2021-12-20       Impact factor: 4.711

7.  CircSERPINA3 regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of prostate cancer cells by competitively binding to MiR-653-5p and recruiting BUD13.

Authors:  Zengshu Xing; Sailian Li; Zhenxiang Liu; Chong Zhang; Zhiming Bai
Journal:  J Transl Med       Date:  2021-12-03       Impact factor: 5.531

8.  Bioelectrical Impedance Vector Pattern and Biomarkers of Physical Functioning of Prostate Cancer Survivors in Rehabilitation.

Authors:  Alexander Stäuber; Marc Heydenreich; Peter R Wright; Steffen Großmann; Niklas Grusdat; Dirk-Henrik Zermann; Henry Schulz
Journal:  Rehabil Process Outcome       Date:  2021-12-16

9.  Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.

Authors:  Qi Li; Yibo Shi; Rigai Sa; Jun Hao; Jinhao Hu; Mulun Xiao; Chaoliang Wang; Liang Yan; Baoping Qiao; Guoxun Chen
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

10.  Long non-coding RNA LINC00673 silencing inhibits proliferation and drug resistance of prostate cancer cells via decreasing KLF4 promoter methylation.

Authors:  Zhenming Jiang; Yuxi Zhang; Xi Chen; Pingeng Wu; Dong Chen
Journal:  J Cell Mol Med       Date:  2019-12-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.